Padcev (enfortumab vedotin-ejfv) - Astellas, Pfizer
Amplification, expression and regulation of Nectin-4 in melanomas and sensitivity to the antibody-drug conjugate enfortumab vedotin (ADO 2026) - Sep 7, 2026 - Abstract #KV 091; Pres time: Sep 11, 2026; 08:10 AM - 08:15 AM; Location: White Hall; No abstract available 
ADC • Melanoma • Solid Tumor • NECTIN4
https://programme.conventus.de/ado-2026/program/program-points/e1585b72-2567-49ae-b551-46fe27b32803
 
Sophie Steinbuch; Dorothée Bouschery; Frank Splettstoesser; Jan Kleiner; PD Dr. Stilla Frede; Prof. Jennifer Landsberg; PD Dr. Dimo Dietrich
 
Sep 7, 2026
 
Prev Next